Free Trial

Lantheus (LNTH) Competitors

Lantheus logo
$81.31 -2.52 (-3.01%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$81.07 -0.24 (-0.30%)
As of 07/11/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LNTH vs. TEVA, INSM, SMMT, ITCI, GMAB, RDY, MRNA, RGC, VTRS, and ASND

Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

Lantheus vs. Its Competitors

Teva Pharmaceutical Industries (NYSE:TEVA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, Teva Pharmaceutical Industries had 3 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Teva Pharmaceutical Industries and 8 mentions for Lantheus. Lantheus' average media sentiment score of 1.45 beat Teva Pharmaceutical Industries' score of 0.78 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
4 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lantheus
6 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Teva Pharmaceutical Industries currently has a consensus price target of $24.71, suggesting a potential upside of 50.79%. Lantheus has a consensus price target of $131.20, suggesting a potential upside of 61.36%. Given Lantheus' higher probable upside, analysts clearly believe Lantheus is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.25
Lantheus
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 1.5% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.

Lantheus has a net margin of 16.55% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Lantheus' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries-7.74% 45.44% 6.95%
Lantheus 16.55%36.99%20.55%

Lantheus has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.62B1.13-$1.64B-$1.15-14.25
Lantheus$1.54B3.66$312.44M$3.5223.10

Summary

Lantheus beats Teva Pharmaceutical Industries on 10 of the 17 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNTH vs. The Competition

MetricLantheusMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$5.63B$10.44B$5.62B$9.09B
Dividend YieldN/A2.06%5.24%4.00%
P/E Ratio23.1016.5428.1320.27
Price / Sales3.6630.17428.2698.57
Price / Cash11.8222.9637.4658.16
Price / Book5.203.668.045.49
Net Income$312.44M$235.43M$3.18B$250.45M
7 Day Performance2.65%1.27%3.62%4.79%
1 Month Performance1.46%2.95%4.06%7.68%
1 Year Performance-34.12%-15.74%30.01%16.43%

Lantheus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LNTH
Lantheus
4.5774 of 5 stars
$81.31
-3.0%
$131.20
+61.4%
-34.2%$5.63B$1.54B23.10700News Coverage
Positive News
TEVA
Teva Pharmaceutical Industries
4.2613 of 5 stars
$16.84
-1.0%
$24.13
+43.3%
-4.2%$19.31B$16.54B-14.6436,830
INSM
Insmed
4.3577 of 5 stars
$96.95
-0.9%
$106.80
+10.2%
+27.5%$18.39B$363.71M-16.291,271Analyst Forecast
Insider Trade
SMMT
Summit Therapeutics
2.8298 of 5 stars
$22.61
-7.9%
$34.67
+53.3%
+188.0%$16.79B$700K-66.50110Gap Down
ITCI
Intra-Cellular Therapies
0.6633 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
4.1076 of 5 stars
$20.52
+1.1%
$37.60
+83.2%
-18.4%$13.16B$3.12B11.662,682Positive News
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7685 of 5 stars
$15.08
flat
$16.95
+12.4%
-7.9%$12.59B$3.81B22.8527,811
MRNA
Moderna
4.309 of 5 stars
$29.90
-1.9%
$46.61
+55.9%
-72.6%$11.56B$3.24B-3.425,800Trending News
RGC
Regencell Bioscience
0.3725 of 5 stars
$18.43
-19.8%
N/AN/A$11.37BN/A0.0010Gap Down
VTRS
Viatris
2.9016 of 5 stars
$9.20
-1.3%
$10.40
+13.0%
-18.5%$10.80B$14.74B-2.9032,000
ASND
Ascendis Pharma A/S
3.5819 of 5 stars
$175.98
+1.0%
$220.67
+25.4%
+28.9%$10.76B$393.54M-28.021,017News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:LNTH) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners